Inspired by Pfizer’s response to the COVID pandemic, Miguel Agreda ’25 brought his skills as a joint-degree MBA/MPH student ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Shares of Pfizer Inc. PFE shed 0.27% to $29.75 Wednesday, on what proved to be an all-around dismal trading session for the ...

The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for ...

Shares of Pfizer Inc. PFE dropped 0.81% to $29.42 Friday, on what proved to be an all-around mixed trading session for the ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

Pharmaceutical giant Pfizer ( PFE 2.73%) stands out in this context. The company currently offers a mouthwatering 5.7% ...

Pfizer reported at #ESMO that an experimental antibody helped cancer patients with a condition known as cachexia.

Acepodia, a start-up developing cell therapies, is collaborating with Pfizer Ignite, which will offer research and development support for drug candidates targeting autoimmune diseases. Acepodia is ...